在奥希替尼治疗的 EGFR 突变型 NSCLC 中检测和应对耐药突变。
PIKing up and AKTing on Resistance Mutations in Osimertinib-Treated EGFR-Mutated NSCLC.
机构信息
Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
出版信息
Clin Cancer Res. 2024 Sep 13;30(18):3968-3970. doi: 10.1158/1078-0432.CCR-24-1188.
A recent study identified high rates of PI3K-AKT pathway mutations from the FLAURA and AURA3 osimertinib trials and pre-clinically validated that these mutations decreased osimertinib sensitivity in EGFR-mutated non-small cell lung cancer. The AKT inhibitor capivasertib was found to overcome this resistance, providing an important rationale for the development of AKT inhibitors in non-small cell lung cancer. See related article by Grazini et al., p. 4143.
一项近期研究在 FLAURA 和 AURA3 奥希替尼试验中鉴定出 PI3K-AKT 通路突变的高发生率，并通过临床前验证发现这些突变降低了 EGFR 突变型非小细胞肺癌对奥希替尼的敏感性。发现 AKT 抑制剂卡培他滨可克服这种耐药性，为 AKT 抑制剂在非小细胞肺癌中的开发提供了重要依据。参见 Grazini 等人的相关文章，第 4143 页。
Zotero 插件